MyMedR

Fulltext Otitis externa complicated with chloramphenicol ear drops-induced perichondritis

Mohamad I, Johan K, Hashim H, Nik Othman N

Malays Fam Physician, 2014;9(1):28-9.

Otitis externa is a common condition of the ear. It is manifested as narrowing of the lumen owing to the edematous swelling of the ear canal lining. Perichondritis may occur independently or as a complication of the otitis externa. We report a case of perichondritis after using a topical ear drop. Changing the medication provides immediate resolution of the condition.

Fulltext A child with coated tonsils

Appannan VR, Mohamad I, Ramli RR, Johan KB

Malays Fam Physician, 2018;13(1):55-56.

PMID: 29796214 MyJurnal

A 5-year-old girl presented with a history of
fever for four days associated with odynophagia.
She was treated with amoxycillin prescribed
by a general practitioner for 3 days prior to
presentation. However, the symptoms were
worsening and associated with drooling of
saliva and poor oral intake. There was history
of recurrent acute tonsillitis in the past two
years, with 5 to 6 episodes per year. The child
had completed regular immunizations up to her
current age. There was no similar presentation
amongst family members and friends. (Copied from article).

Fulltext A man with red pinna and yellow discharge

Misron K, Mohamad I, Nik Adilah NO, Johan KB

Malays Fam Physician, 2015;10(3):43-4.

PMID: 27570610

Fulltext In the finger it lingers

Mohd AW, Mohamad I, Wan Ghazali WS, Johan KB

Malays Fam Physician, 2017;12(2):32-33.

PMID: 29423129 MyJurnal

A previously healthy 80-year-old woman presented with a history of a thorn prick injury over the
distal phalange of her left finger obtained while gardening two months ago. She claimed to have a
non-healing cut with a nodular lesion, which progressively increased in size, extending upwards
towards the region of her left arm. There was no fever or palpable lymph nodes in the axillary region.
She had been prescribed antibiotics from the local hospital but her condition did not improve.

Recombinant activated factor VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-year single-centre experience

Shah NM, Chong SE, Yusoff SM, Mazlan MZ, Johan KB, Azman N, et al.

BMC Hematol, 2018;18:34.

PMID: 30498571 DOI: 10.1186/s12878-018-0126-z

Background: Massive bleeding is one of the commonest salvageable causes of death. The search for an ideal haemostatic agent during massive bleeding is still ongoing. One of the novel haemostatic medications is recombinant activated factor VII (rFVIIa). To date, the usage of rFVIIa during massive haemorrhage among non-haemophiliac patients remains off-label. The aim of this study is to report our experience in using rFVIIa to treat refractory bleeding.

Methods: Medical records of all patients treated with rFVIIa for massive bleeding over an eleven-year period in a single institution were recorded. Treatment indications, 24-h and 30-day mortality, changes in transfusion needs and coagulation profiles after rFVIIa administration were analysed.

Results: rFVIIa were administered in 76 patients. Of these, 41 (53.9%) were non-surgical bleeding, followed by 22 patients (28.9%) with trauma, other surgery bleedings in 9 patients (11.8%) and 4 patients (5.4%) with peripartum haemorrhage. Total survival rate was 78.9% within 24 h and 44.7% over 30 days. Among all these patients who had received rFVIIa due to life-threatening haemorrhage, blood and blood product requirements were significantly reduced (P

Displaying all 5 publications